HARVARD BIOSCIENCE INC (HBIO)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

2Y 5Y 10Y All
Quarterly Annual TTM

Revenue Annual

0 50M 100M 150M FY09: 85.8M FY10: 108.2M FY11: 108.9M FY12: 111.2M FY13: 105.2M FY14: 108.7M FY15: 108.7M FY16: 104.5M FY17: 77.4M FY18: 120.8M FY19: 116.2M FY20: 102.1M FY21: 118.9M FY22: 113.3M FY23: 112.2M FY24: 94.1M FY25: 86.5M FY09 FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Gross Profit Annual

0 25M 50M 75M FY09: 41.7M FY10: 51.8M FY11: 50.2M FY12: 52.3M FY13: 47.7M FY14: 49.3M FY15: 48.7M FY16: 48.4M FY17: 39.2M FY18: 63.2M FY19: 64.3M FY20: 58M FY21: 67.7M FY22: 60.8M FY23: 66.1M FY24: 54.8M FY25: 49.9M FY09 FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Operating Income Annual

-60M -40M -20M 0 20M 40M 60M FY09: 8.1M FY10: 10.2M FY11: 8.4M FY12: 7.8M FY13: 1.5M FY14: 6.6M FY15: -1.7M FY16: -3M FY17: -635K FY18: 984K FY19: 377K FY20: 221K FY21: 2.1M FY22: -6.9M FY23: 1.9M FY24: -6.2M FY25: -48.6M FY09 FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Net Income Annual

-60M -40M -20M 0 20M 40M 60M FY09: 7.2M FY10: 19M FY11: 3.8M FY12: 2.4M FY13: -1.8M FY14: 2.4M FY15: -19M FY16: -4.3M FY17: -865K FY18: -2.9M FY19: -4.7M FY20: -7.8M FY21: -288K FY22: -9.5M FY23: -3.4M FY24: -12.4M FY25: -56.7M FY09 FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Cost of Revenue Annual

0 25M 50M 75M FY09: 44.1M FY10: 56.4M FY11: 58.7M FY12: 58.8M FY13: 57.5M FY14: 59.3M FY15: 59.9M FY16: 56.1M FY17: 38.2M FY18: 57.6M FY19: 51.9M FY20: 44.1M FY21: 51.3M FY22: 52.5M FY23: 46.2M FY24: 39.4M FY25: 36.6M FY09 FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Operating Cash Flow Annual

0 6M 12M 18M FY09: 16.5M FY10: 12.3M FY11: 6.6M FY12: 8.1M FY13: 4.1M FY14: 4.4M FY15: 705K FY16: 5.4M FY17: 1.1M FY18: 2.9M FY19: 8M FY20: 9.3M FY21: 1.3M FY22: 1.2M FY23: 14M FY24: 1.4M FY25: 6.7M FY09 FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Free Cash Flow Annual

-5M 0 5M 10M 15M FY17: 167K FY18: 1.9M FY19: 6.8M FY20: 8.2M FY21: 67K FY22: -438K FY23: 12.2M FY24: -1.2M FY25: 5.5M FY17 FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25

Operating cash flow minus capital expenditure.

Shares Outstanding Annual

0 20M 40M 60M FY09: 29.9M FY10: 29.4M FY11: 29.8M FY12: 29.8M FY13: 31.9M FY14: 33.2M FY15: 33.6M FY16: 34.2M FY17: 34.8M FY18: 36.5M FY19: 37.8M FY20: 38.6M FY21: 40.3M FY22: 41.4M FY23: 42.4M FY24: 43.5M FY25: 44.4M FY09 FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-15.00 -10.00 -5.00 0.00 5.00 10.00 15.00 Q4 '10: 0.65 Q1 '11: 0.64 Q2 '11: 0.63 Q3 '11: 0.19 Q4 '11: 0.13 Q1 '12: 0.09 Q2 '12: 0.07 Q3 '12: 0.07 Q4 '12: 0.09 Q1 '13: 0.07 Q2 '13: 0.03 Q3 '13: 0.00 Q4 '13: -0.06 Q1 '14: -0.04 Q2 '14: 0.00 Q3 '14: 0.05 Q4 '14: 0.07 Q1 '15: 0.01 Q2 '15: -0.01 Q3 '15: -0.05 Q4 '15: -0.56 Q1 '16: -0.54 Q2 '16: -0.57 Q3 '16: -0.60 Q4 '16: -0.13 Q1 '17: -0.14 Q2 '17: -0.13 Q3 '17: -0.09 Q4 '17: -0.02 Q1 '18: -0.10 Q2 '18: -0.13 Q3 '18: -0.13 Q4 '18: -0.08 Q1 '19: -0.03 Q2 '19: 0.00 Q3 '19: -0.06 Q4 '19: -0.12 Q1 '20: -0.18 Q3 '21: -0.04 Q4 '21: -0.01 Q1 '22: -0.16 Q2 '22: -0.09 Q3 '22: -0.17 Q4 '22: -0.23 Q1 '23: -0.05 Q2 '23: -0.13 Q3 '23: -0.08 Q4 '23: -0.08 Q1 '24: -0.20 Q2 '24: -0.25 Q3 '24: -0.33 Q4 '24: -0.28 Q1 '25: -11.59 Q2 '25: -12.04 Q3 '25: -11.96 Q1 '12 Q4 '13 Q3 '15 Q2 '17 Q1 '19 Q1 '22 Q4 '23 Q3 '25

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.